TG Therapeutics
TGTX
66 hedge funds and large institutions have $165M invested in TG Therapeutics in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 10 closing their positions.
566% more call options, than puts
Call options by funds: $8.51M | Put options by funds: $1.28M
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
35% more capital invested
Capital invested by funds: $122M → $165M (+$43.1M)
1% less funds holding
Funds holding: 67 → 66 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.2M |
| 2 |
BM
Bridger Management
New York
|
+$9.71M |
| 3 |
VAM
Visium Asset Management
New York
|
+$1.95M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$1.09M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$871K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$6.01M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$2.96M |
| 3 |
Millennium Management
New York
|
-$1.24M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.03M |
| 5 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$770K |
TGTX Hedge Fund Activity: Q3 2014 in Review
66 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2014, worth a combined $165M — up 35% from $122M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TGTX and 9 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 32 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $19.2M. The largest seller was JP Morgan Chase, cutting an estimated $6.01M.
- 66 institutional investors held TG Therapeutics (TGTX) as of Q3 2014, down from 67 in Q2 2014.
- Funds reported $165M of TG Therapeutics stock for Q3 2014, up 35% quarter-over-quarter.
- 9 funds opened new TG Therapeutics positions in Q3 2014 and 10 closed out, a net change of -1 holder.
- The largest TG Therapeutics buyer in Q3 2014 was RA Capital Management, an estimated $19.2M added.
- The largest TG Therapeutics seller in Q3 2014 was JP Morgan Chase, an estimated $6.01M sold.
Based on aggregated 13F filings for Q3 2014.